DEF: Dentsply Sirona 2026 Proxy Statement Overview

Dentsply Sirona's 2026 proxy statement outlines the upcoming annual meeting agenda, including director elections, executive compensation approval, and a request to increase shares under the 2024 Omnibus Incentive Plan.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 2, 2026, to be held virtually.
• Key agenda items include the election of twelve director nominees, ratification of Deloitte & Touche LLP as independent auditors, an advisory vote on 2025 executive compensation, and approval of Amendment No. 2 to the 2024 Omnibus Incentive Plan.
• Amendment No. 2 seeks to increase the number of shares issuable under the 2024 Plan by 15,000,000 shares.
• The company reported 2025 net sales of $3.68 billion, representing a 3.0% decrease from 2024.
• The 2025 adjusted EBITDA margin was 18.1%, compared to 16.6% in 2024.
• The company experienced significant executive leadership transitions in 2025, including the appointment of Daniel T. Scavilla as President and CEO.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-cautious filing, reflecting a company in the midst of a significant turnaround, leadership turnover, and declining financial performance, despite efforts to align governance and compensation with long-term recovery.

Positives

• Adjusted EBITDA margin improved to 18.1% in 2025 from 16.6% in 2024.
• The company successfully reached its five-year target to enable and empower 25 million smiles.
• Maintained total average gender pay parity across the global workforce.
• Workplace safety performance surpassed the 2025 goal with a total recordable incident rate of 0.22.
• Strong stockholder support for executive compensation in 2025, with approximately 97.2% voting affirmatively.

Negatives

• Net sales declined by 3.0% to $3.68 billion in 2025.
• Organic sales decreased by 4.3% in 2025.
• Reported a GAAP loss per basic common share of $3.00 in 2025.
• Adjusted earnings per diluted share decreased to $1.60 from $1.67 in 2024.
• Significant executive turnover occurred throughout 2025, including the CEO, CFO, and General Counsel.

Risks

• Ability to remain profitable in a highly competitive marketplace.
• Potential need to record additional impairment charges if assumptions and projections are not realized.
• Risks associated with changes to distribution channels and management of distributor inventories.
• Increased regulation impacting business operations.
• Failure to receive regulatory authorization for new product or service offerings.
• Macroeconomic conditions, including recession risks, inflation, and higher interest rates.
• Failure to realize expected benefits from cost reduction and restructuring efforts.

Future Outlook

The company is focused on its 'Return-to-Growth Action Plan' announced in November 2025, which includes five pillars: customer-centric mindset, reigniting sustainable growth, empowering performance, scaling the organization, and financial strength.

Management Comments

• The Board believes that having a non-executive Chairman is in the best interests of the Company and our stockholders at this time.
• The Board believes that the success of the Company is largely dependent on its ability to attract, retain and motivate highly-qualified employees and non-employee directors.
• The company is committed to running an ethical and transparent business, and works hard to foster trusted relationships with our employees, customers, partners and stockholders.

Industry Context

StockSavvy.ai notes that Dentsply Sirona is navigating a challenging period of leadership transition and business model restructuring within the competitive dental equipment and supplies industry, mirroring broader trends of consolidation and the need for digital transformation.

Comparison to Industry Standards

• The company benchmarks its executive compensation against a peer group of 19 companies, including Align Technology, Hologic, and Zimmer Biomet.
• The company's safety performance remains within the top decile among medium-sized companies.
• The company's target total direct compensation for executives is typically around the 50th percentile of the market.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed in the filing.

Related Party Transactions

• None noted for the year ended December 31, 2025.

Stakeholder Impact

• Shareholders are asked to vote on director elections and an increase in shares for the incentive plan.
• Employees are subject to ongoing restructuring and cost-reduction efforts.
• Customers are the focus of the new 'Customer-Centric Mindset' pillar.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 2, 2026.
• Execute the 'Return-to-Growth Action Plan' to improve performance.
• Continue to integrate sustainability initiatives under the 'BEYOND' framework.

Key Dates

Recommendation

The company is in a clear turnaround phase with significant leadership changes and declining financial metrics. While the governance structure is robust, investors should wait for evidence that the 'Return-to-Growth' plan is yielding tangible improvements in sales and profitability before increasing exposure.

Keywords

Dentsply Sirona, XRAY, Proxy Statement, Executive Compensation, Dental Technology, Corporate Governance, Annual Meeting